New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer
Study
Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02)
|
HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast cancer
|
Trastuzumab-deruxdeca (n=406) vs. SOC (n=202)
|
|
Efficacy
mPFS: 17.8 vs 6.9 mos, p<0.0001
|
12 months PFS: 62% vs. 27%
|
24 months PFS: 42% vs 13%
|
mOS: 39.2 vs. 26.5 mos, p=0021
|
12 months OS: 89.4% vs.74.7%
|
24 months OS: 65.9% vs.54.3%
|
Safety
Grade≥3 AEs: Neutropenia (11% vs 2%), Anemia (8% vs. 3%), nausea (7% vs 3%), palmar-plantar erythrodysesthesia (1% vs 10%), diarrhea (3% vs. 7%)
|
Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomized, open-label, multicentre, phase 3 trial
Reviewed by Elvin Chalabiyev, MD on May 20, 2023
